Work

Agomelatine Monotherapy for Autism—A Case Report

Year: 2025

Type: article

Abstract: ASD is commonly associated with a host of challenging behaviours. Pharmacotherapy is indicated if psycho-social and educational interventions fail. Atypical antipsychotics have the strongest evidence-base so far, with both risperidone and aripiprazole are FDA-approved. Unfortunately, their use is fraught with metabolic and neuro-hormonal side effects. Here, authors report on a case of ASD/mild ID with behavioural dyscontrol that failed multiple psychotropic trials and ultimately responded favourably to agomelatine monotherapy. This was achieved with excellent tolerability. This might open new venues in such complicated cases.

Source: Psychopharmacology Bulletin

DOI: 10.64719/pb.4454

Authors: Ahmed Naguy, Saxby Pridmore, Mohammed A Jamali, Alaa Eisa Hasan, Bibi Alamiri

Institutions: University of Tasmania, Ministry of Education, Kuwait, Tufts University

Language: English

Topic: Autism Spectrum Disorder Research

Subfield: Cognitive Neuroscience

Field: Neuroscience

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4308552556

FWCI:

Cites: 7

Cited by: 1

Related to: 10